Literature DB >> 26000825

Antitumor and antimetastatic effects of pemetrexed-loaded targeted nanoparticles in B16 bearing mice.

Nannan Lu1, Rutian Li2, Qin Liu2, Bing Hu1, Xiaoling Xu3, Chushu Ji1, Xinghua Han1, Pin Wang4, Baorui Liu2.   

Abstract

Using nanoparticle delivery for anticancer therapy is a potential new drug modality. We developed a novel gelatinase-stimuli nanoparticle. In this study, we studied the antitumor and antimetastasis effect of pemetrexed-loaded targeted nanoparticles and evaluated the correlation between E-cadherin expression and lung metastasis in subcutaneous xenograft model. Compared with free pemetrexed, pemetrexed-loaded targeted nanoparticles exhibited the best antitumor and antimetastasis efficacy among the four therapeutic groups. The study also indicated that there was an inverse correlation between lung metastasis and E-cadherin expression. These results showed pemetrexed-loaded targeted nanoparticles may be a potent drug for tumor therapy and our preclinical data could provide new direction for clinical therapy of malignant melanoma.

Entities:  

Keywords:  Antimetastsis; PEG–Peptide–PCL nanoparticles; antitumor; drug delivery; pemetrexed

Mesh:

Substances:

Year:  2015        PMID: 26000825     DOI: 10.3109/10717544.2015.1033794

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  3 in total

1.  EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma.

Authors:  Liang Yang; Hanghang Fang; Jingjing Jiang; Yongjie Sha; Zhiyuan Zhong; Fenghua Meng
Journal:  Drug Deliv Transl Res       Date:  2021-11-20       Impact factor: 5.671

2.  A novel gene expression-based prognostic scoring system to predict survival in gastric cancer.

Authors:  Pin Wang; Yunshan Wang; Bo Hang; Xiaoping Zou; Jian-Hua Mao
Journal:  Oncotarget       Date:  2016-08-23

3.  Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy.

Authors:  Juan Chen; Xiaobing Yang; Liuqing Huang; Huixian Lai; Chuanhai Gan; Xuetao Luo
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.